Ibalizumab

Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection[1][2].

Product Specifications

CAS Number

[680188-33-4]

Product Name Alternative

TMB-355; TNX-355

UNSPSC

12352203

Target

HIV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ibalizumab.html

Purity

99.91

Solubility

H2O

Smiles

[Ibalizumab]

Molecular Weight

(147.36 kDa)

References & Citations

[1]Zhu L, et al. Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration. Nat Commun. 2024 Aug 13;15 (1) :6961.|[2]Beccari MV, et al. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob Agents Chemother. 2019 May 24;63 (6) :e00110-19.